These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 26686699)
21. β-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis. Huss S; Nehles J; Binot E; Wardelmann E; Mittler J; Kleine MA; Künstlinger H; Hartmann W; Hohenberger P; Merkelbach-Bruse S; Buettner R; Schildhaus HU Histopathology; 2013 Jan; 62(2):294-304. PubMed ID: 23020601 [TBL] [Abstract][Full Text] [Related]
22. A Metabolomics Pilot Study on Desmoid Tumors and Novel Drug Candidates. Mercier KA; Al-Jazrawe M; Poon R; Acuff Z; Alman B Sci Rep; 2018 Jan; 8(1):584. PubMed ID: 29330550 [TBL] [Abstract][Full Text] [Related]
23. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool. Amary MF; Pauwels P; Meulemans E; Roemen GM; Islam L; Idowu B; Bousdras K; Diss TC; O'Donnell P; Flanagan AM Am J Surg Pathol; 2007 Sep; 31(9):1299-309. PubMed ID: 17721184 [TBL] [Abstract][Full Text] [Related]
24. Human microRNA expression in sporadic and FAP-associated desmoid tumors and correlation with beta-catenin mutations. Cavallini A; Rotelli MT; Lippolis C; Piscitelli D; Digennaro R; Covelli C; Carella N; Accetturo M; Altomare DF Oncotarget; 2017 Jun; 8(26):41866-41875. PubMed ID: 28418912 [TBL] [Abstract][Full Text] [Related]
25. Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis. Jilong Y; Jian W; Xiaoyan Z; Xiaoqiu L; Xiongzeng Z Pathology; 2007 Jun; 39(3):319-25. PubMed ID: 17558858 [TBL] [Abstract][Full Text] [Related]
26. CTNNB1 genotyping and APC screening in pediatric desmoid tumors: a proposed algorithm. Wang WL; Nero C; Pappo A; Lev D; Lazar AJ; López-Terrada D Pediatr Dev Pathol; 2012; 15(5):361-7. PubMed ID: 22372443 [TBL] [Abstract][Full Text] [Related]
27. Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells. Li J; Chen X; Dong X; Xu Z; Jiang H; Sun X J Gastroenterol Hepatol; 2006 Dec; 21(12):1814-20. PubMed ID: 17074019 [TBL] [Abstract][Full Text] [Related]
28. Possible association between higher beta-catenin mRNA expression and mutated beta-catenin in sporadic desmoid tumors: real-time semiquantitative assay by TaqMan polymerase chain reaction. Saito T; Oda Y; Kawaguchi K; Tanaka K; Matsuda S; Tamiya S; Iwamoto Y; Tsuneyoshi M Lab Invest; 2002 Jan; 82(1):97-103. PubMed ID: 11796830 [TBL] [Abstract][Full Text] [Related]
29. Expression and significance of Wnt signaling components and their target genes in breast carcinoma. He Y; Liu Z; Qiao C; Xu M; Yu J; Li G Mol Med Rep; 2014 Jan; 9(1):137-43. PubMed ID: 24190141 [TBL] [Abstract][Full Text] [Related]
30. Intrathoracic sporadic desmoid tumor with the beta-catenin gene mutation in exon 3 and activated cyclin D1. Tajima S; Hironaka M; Oshikawa K; Bando M; Ohno S; Saito K; Sohara Y; Sugiyama Y Respiration; 2006; 73(4):558-61. PubMed ID: 16131791 [TBL] [Abstract][Full Text] [Related]
31. Is mutation analysis of β-catenin useful for the diagnosis of desmoid-type fibromatosis? A systematic review. Sakai T; Hamada S; Koike H; Shimizu K; Yoshida M; Nishida Y Jpn J Clin Oncol; 2020 Sep; 50(9):1037-1042. PubMed ID: 32533146 [TBL] [Abstract][Full Text] [Related]
32. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Crago AM; Chmielecki J; Rosenberg M; O'Connor R; Byrne C; Wilder FG; Thorn K; Agius P; Kuk D; Socci ND; Qin LX; Meyerson M; Hameed M; Singer S Genes Chromosomes Cancer; 2015 Oct; 54(10):606-15. PubMed ID: 26171757 [TBL] [Abstract][Full Text] [Related]
33. Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors. Braggio DA; Costas C de Faria F; Koller D; Jin F; Zewdu A; Lopez G; Batte K; Casadei L; Welliver M; Horrigan SK; Han R; Larson JL; Strohecker AM; Pollock RE PLoS One; 2022; 17(10):e0276047. PubMed ID: 36240209 [TBL] [Abstract][Full Text] [Related]
34. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Colombo C; Miceli R; Lazar AJ; Perrone F; Pollock RE; Le Cesne A; Hartgrink HH; Cleton-Jansen AM; Domont J; Bovée JV; Bonvalot S; Lev D; Gronchi A Cancer; 2013 Oct; 119(20):3696-702. PubMed ID: 23913621 [TBL] [Abstract][Full Text] [Related]
35. Droplet Digital PCR (ddPCR) as a Novel Technology in Detecting CTNNB1 Mutations in Desmoid Fibromatosis. Gandhi J; Kao E; Wu Y; Mantilla JG; Ricciotti RW; Bandhlish A; Liu YJ; Chen EY Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):662-667. PubMed ID: 36227098 [TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of Guo L; Wang X; Xu B; Lang R; Hu B Future Oncol; 2021 Feb; 17(4):435-442. PubMed ID: 33397129 [No Abstract] [Full Text] [Related]
37. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Le Guellec S; Soubeyran I; Rochaix P; Filleron T; Neuville A; Hostein I; Coindre JM Mod Pathol; 2012 Dec; 25(12):1551-8. PubMed ID: 22766794 [TBL] [Abstract][Full Text] [Related]
38. beta-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours. Saito T; Oda Y; Tanaka K; Matsuda S; Tamiya S; Iwamoto Y; Tsuneyoshi M J Pathol; 2001 Sep; 195(2):222-8. PubMed ID: 11592102 [TBL] [Abstract][Full Text] [Related]
39. Clinicopathological analysis of β-catenin and Axin-1 in solid pseudopapillary neoplasms of the pancreas. Huang SC; Ng KF; Yeh TS; Chang HC; Su CY; Chen TC Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S438-46. PubMed ID: 21769465 [TBL] [Abstract][Full Text] [Related]